Synairgen plc (AIM: SNG)
London flag London · Delayed Price · Currency is GBP · Price in GBX
4.311
-0.249 (-5.46%)
Nov 7, 2024, 12:01 PM GMT+1

Synairgen Company Description

Synairgen plc discovers and develops drugs for respiratory diseases.

It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses.

Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Synairgen plc
Country United Kingdom
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 36
CEO Richard Marsden

Contact Details

Address:
Mailpoint 810
Southampton, SO16 6YD
United Kingdom
Phone 44 23 8051 2800
Website synairgen.com

Stock Details

Ticker Symbol SNG
Exchange London Stock Exchange AIM
Fiscal Year January - December
Reporting Currency GBP
ISIN Number GB00B0381Z20
SIC Code 2836

Key Executives

Name Position
Richard Marsden Chief Executive Officer
Joseph Colliver Chief Financial Officer